 |
245 Diseases |  |
389 Trials |
|
389 Trials |  |
11400 News |  |
| «12...3233343536373839404142...143144» |
- adagrasib (MRTX849) / Mirati, Erbitux (cetuximab) / Eli Lilly, EMD Serono
KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation (7.2.F - Fécamp Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1490;
P1/2, P3
Both showed clinical activity in heavily pretreated pts with KRAS G12C -mutated CRC, with more sustained responses with the combination. Adagrasib + cetuximab is being investigated in 2L CRC in the Phase 3 KRYSTAL-10 trial (NCT04793958).
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase III study with FOLFIRI/cetuximab versus FOLFIRI/cetuximab followed by cetuximab (Cet) alone in first-line therapy of RAS and BRAF wild-type (wt) metastatic colorectal cancer (mCRC) patients: The ERMES study (4.A - Antibes Auditorium) - Jul 25, 2022 - Abstract #ESMO2022ESMO_1412;
P3
The ITT analysis and OS results are suggestive for a strategy of de-escalation treatment with only cetuximab. Ongoing translational analyses might allow to select pts benefitting from de-escalation strategy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Monotherapy, Metastases: ABORL: Evaluation of ABEMACICLIB Monotherapy in Patients With Locally Advanced/Metastatic Head and Neck Cancer After Failure of Platinum and Cetuximab or Anti-EGFR-based Therapy and Harboring an Homozygous Deletion of CDKN2A, and/or an Amplification of CCND1 and/or of CDK6 (clinicaltrials.gov) - Jul 25, 2022
P2, N=25, Recruiting, Sponsor: Centre Leon Berard
Ongoing translational analyses might allow to select pts benefitting from de-escalation strategy. Trial completion date: Sep 2022 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Tagrisso (osimertinib) / AstraZeneca, Gilotrif (afatinib) / Boehringer Ingelheim
Journal: Molecular mechanism study of EGFR allosteric inhibitors using molecular dynamics simulations and free energy calculations. (Pubmed Central) - Jul 23, 2022
ABTRACTThe epidermal growth factor receptor (EGFR) kinase inhibitors Gefitinib, Erlotinib, Afatinib and Osimertinib have been approved for the treatments of non-small cell lung cancer patients harboring sensitive EGFR mutations, but resistance arises rapidly...However, it was not effective as a single-agent inhibitor, and require the co-administration of the anti-EGFR antibody Cetuximab...The identified key features obtained from the molecular modeling enabled us to design novel EGFR allosteric inhibitors. Communicated by Ramaswamy H. Sarma.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal: Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy. (Pubmed Central) - Jul 23, 2022
This group was also shown to activate CD8 T lymphocytes in lymph nodes and accumulate CD8 T lymphocytes to a greater extent within the tumor compared with the control group. These results showed that APCs with longer half-life and double light exposure lead to superior outcomes in cancer cell-targeted NIR-PIT in an immunocompetent mouse model.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker, IO biomarker: Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. (Pubmed Central) - Jul 23, 2022
P3
Results from the PD-L1 CPS 1-19 subgroup support previous findings of treatment benefit with pembrolizumab monotherapy and pembrolizumab-chemotherapy in patients with PD-L1 CPS ≥ 1 tumors. Although PD-L1 expression is informative, exploration of additional predictive biomarkers is needed for low PD-L1-expressing HNSCC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal, IO biomarker: Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology. (Pubmed Central) - Jul 23, 2022
The combination of phage display and site-directed mutagenesis allowed mutational screening of antigen surface, showing polyclonal antibodies' recognition of mutated receptor escape variants known to arise in patients under the selective pressure of the anti-HER-1 antibody cetuximab. Phage-displayed HER domains have thus the potential to contribute to fine specificity characterization of humoral responses during future development of anti-cancer vaccines.
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Review, Journal: Postoperative radiotherapy with cetuximab for head and neck squamous cell carcinoma patients at high risk of recurrence not eligible for cisplatin: A single-center experience and literature review (Pubmed Central) - Jul 23, 2022
In our single-center retrospective analysis, postoperative radiotherapy with cetuximab for patients with high-risk head and neck cancer ineligible for cisplatin showed similar outcomes to the literature data for exclusive postoperative radiotherapy, with a high discontinuation rate. These low-power data support the lack of indication for cetuximab in combination with postoperative radiotherapy.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
New P2 trial, Combination therapy, Metastases: CIFOXRC: Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer (clinicaltrials.gov) - Jul 21, 2022
P2, N=66, Recruiting, Sponsor: Tongji Hospital
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Trial primary completion date, Metastases: Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 20, 2022
P1/2, N=38, Recruiting, Sponsor: M.D. Anderson Cancer Center
These low-power data support the lack of indication for cetuximab in combination with postoperative radiotherapy. Trial primary completion date: Jun 2024 --> Jun 2025
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study. (Pubmed Central) - Jul 20, 2022
There was no difference in survival found between the group of the perioperative chemotherapy plus cetuximab and that of the postoperative chemotherapy in the cohort of our study. The study was registered in the University Hospital Medical Information Network (UMIN000007787).
- |||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: .@SWOG S2107 compares PFS in patients w MSS, BRAF-V600E metastatic or unresectable #colorectalcancer randomized to encorafenib + cetuximab w or w/out nivolumab. BRAF-V600E mutations in ~10% of #CRC diagnoses. Co-PI: @SKopetz @MDAndersonNews https://t.co/jubkzhy3mO (Twitter) - Jul 19, 2022
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Torisel (temsirolimus) / Pfizer
Trial completion date, Trial primary completion date, Combination therapy, Metastases: Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease (clinicaltrials.gov) - Jul 19, 2022
P1, N=155, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
The study was registered in the University Hospital Medical Information Network (UMIN000007787). Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Gilotrif (afatinib) / Boehringer Ingelheim
Circulating tumor DNA: More on the prognostic value of #ctDNA changes with targeted therapy for NSCLC @CCR_AACR. In @SWOG S1403 (1L afatinib +/- cetuximab for #EGFR NSCLC), clearance of EGFR ctDNA by 8w associated with better PFS (15.1 vs 4.6m, HR 0.23) and OS (HR 0.44). #LCSM https://t.co/UCJ96tw7KY (Twitter) - Jul 19, 2022
- Libtayo (cemiplimab) / Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Metastatic scrotal squamous cell carcinoma responding well to EGFR inhibitor cetuximab after progression to PD1 inhibitor cemiplimab (Red Hall) - Jul 18, 2022 - Abstract #ADO2022ADO_251;
- |||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / Ono Pharma, BMS, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: Now enrolling: @SWOG S2107. Patients with #MSS #BRAF-V600E metastatic or unresectable #colorectalcancer with at least 1 prior line systemic therapy. Encorafenib + cetuximab w/wo nivolumab. https://t.co/jubkzhy3mO. PI: @VanMorrisMD @MDAndersonNews (Twitter) - Jul 18, 2022
- ||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial completion date, Combination therapy, Metastases: CheckMate 651: Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jul 18, 2022
P3, N=947, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Mar 2022 --> Mar 2023 Trial completion date: Jun 2022 --> Sep 2022
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Retrospective data, Journal: Radiotherapy plus cetuximab for locally advanced squamous cell head and neck cancer in patients with cisplatin-ineligible renal dysfunction: A retrospective study. (Pubmed Central) - Jul 17, 2022
Adjusted Cox analysis revealed that the risk of death was increased by 2.52-fold (hazard ratio, 2.52; 95% confidence interval, 1.01-6.30; P=0.048) if creatinine clearance was <45 ml/min. Moderate to severe renal dysfunction did not affect the locoregional control rate in patients with LA-SCCHN treated with radiotherapy plus cetuximab but was an adverse prognostic factor.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal, Circulating tumor DNA: Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge. (Pubmed Central) - Jul 17, 2022
P2
Furthermore, excluding these patients from EGFR rechallenge is already being adopted in prospectively done clinical trials, e.g., the CHRONOS study (NCT03227926). Rechecking the liquid biopsy plasma RAS/RAF status is one thing that may be incorporated into practice with EGFR rechallenge only a consideration if acquired mechanisms of resistance are absent.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal: Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis. (Pubmed Central) - Jul 16, 2022
Anti-cancer agents, including cisplatin and temozolomide, also induce the p38-mediated internalization. The results of the present study demonstrate that synchronous non-canonical EGFR endocytosis may be a feasible strategy for promoting the therapeutic efficacy of EGFR-targeting ADCs in clinical settings.
- || Bavencio (avelumab) / EMD Serono, Pfizer, Erbitux (cetuximab) / Eli Lilly, EMD Serono
P2 data, Journal: CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients. (Pubmed Central) - Jul 15, 2022
P2
This study will provide the rationale to test immunotherapy-based combinations in the clinical setting, offering new opportunities for RAS WT mCRC patients. [https://clinicaltrials.gov/ct2/show/NCT05291156], identifier [NCT05291156].
- ||| D3S-001 / D3 Bio
Enrollment open, Combination therapy, Monotherapy, Metastases: A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation (clinicaltrials.gov) - Jul 15, 2022
P1, N=98, Recruiting, Sponsor: D3 Bio (Wuxi) Co., Ltd
[https://clinicaltrials.gov/ct2/show/NCT05291156], identifier [NCT05291156]. Not yet recruiting --> Recruiting
- | Libtayo (cemiplimab-rwlc) / Regeneron, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer (clinicaltrials.gov) - Jul 15, 2022
P1, N=10, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- | Lonsurf (trifluridine/tipiracil) / Servier, Otsuka, Erbitux (cetuximab) / Eli Lilly, EMD Serono, Vectibix (panitumumab) / Amgen, Takeda
Journal, Real-world evidence: Real-World Assessment of Cancer Drugs Using Local Data Uploaded to the Systemic Anti-Cancer Therapy Dataset in England. (Pubmed Central) - Jul 15, 2022
Our results support the publication of national outcome data. If these results are confirmed on a larger cohort, it would support the reappraisal of certain drugs and provide further evidence to clinicians and patients when deciding the best treatment.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Pinnae and facial hypertrichosis induced by cetuximab. (Pubmed Central) - Jul 14, 2022
This distinct entity can be easily diagnosed and manipulated with early drug withdrawal. An extensive review of relevant basic molecular research is provided to increase physicians' awareness.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Early-Onset Colorectal Cancer in a Young Woman with Type 1 Gaucher Disease. (Pubmed Central) - Jul 14, 2022
An extensive review of relevant basic molecular research is provided to increase physicians' awareness. There may be a correlation between the hyperinflammatory background of untreated Gaucher disease and the development of neoplasia.Gaucher disease has rarely been described in association with colorectal cancer.Gaucher disease can be further worsened by chemotherapeutic agents.
- | irinotecan / Generic mfg.
Journal: Irinotecan dose reduction in metastatic colorectal cancer patients with homozygous UGT1A1*28 polymorphism: a single-center case series. (Pubmed Central) - Jul 14, 2022
mCRC patients homozygous for the UGT1A1*28 allele can tolerate irinotecan at an initial dose of 120 mg/m with favorable oncological outcomes and toxicity profiles. Further prospective studies are warranted to optimize irinotecan-based chemotherapy in these patients.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date: NCI-2018-02990: Cetuximab in Head and Neck Cancer Patients (clinicaltrials.gov) - Jul 14, 2022
P2, N=15, Completed, Sponsor: University of Wisconsin, Madison
Further prospective studies are warranted to optimize irinotecan-based chemotherapy in these patients. Active, not recruiting --> Completed | Trial completion date: Jul 2022 --> Mar 2022
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Review, Journal, IO biomarker: Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer. (Pubmed Central) - Jul 13, 2022
The BEACON trial has been the most important therapeutic change in the last decade. Nevertheless, new information regarding biomarkers or novel combinations including BRAF inhibitors plus immune checkpoint inhibitors are also promising.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal, HEOR, Patient reported outcomes: Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC. (Pubmed Central) - Jul 13, 2022
P3
Nevertheless, new information regarding biomarkers or novel combinations including BRAF inhibitors plus immune checkpoint inhibitors are also promising. In addition to improving OS, encorafenib plus cetuximab with or without binimetinib delays QoL decline in previously treated patients with BRAF V600E-mutant mCRC.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer, Mektovi (binimetinib) / Ono Pharma, Pierre Fabre, Pfizer
Journal: Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience. (Pubmed Central) - Jul 13, 2022
Our real-life data are consistent with those from the BEACON trial in terms of safety, activity, and efficacy. Patients in good general condition and not heavily pretreated are those more likely to derive benefit from the targeted treatment.
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Clinical: before there were 2 drugs approved, we @Dr_R_Kurzrock had a creative way to overcome the binding site resistance mechanism (@ADesaiMD posted above) w cetuximab @LillyPad! It worked well for our 3 patients! Glad 🎯drug 🧬development keeps moving forward! https://t.co/WqWEo9M8sC (Twitter) - Jul 12, 2022
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono
Am getting sidetracked here BUT infusion reactions to antibodies like cetuximab can happen… and this had ticked since its amazing discovery- as a cross reaction to certain ticks endemic to Appalachia!!! Science is amazing! https://t.co/PMSC6HQic3 (Twitter) - Jul 12, 2022
- || pegenzileukin (SAR444245) / Sanofi, Innovent Biologics
Trial completion date, Trial primary completion date, Combination therapy, Metastases: HAMMER: A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101) (clinicaltrials.gov) - Jul 12, 2022
P1/2, N=300, Recruiting, Sponsor: Synthorx, Inc, a Sanofi company
Patients in good general condition and not heavily pretreated are those more likely to derive benefit from the targeted treatment. Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023
- || Ibrance (palbociclib) / Pfizer
Enrollment closed, Trial completion date, Metastases: PALATINUS: Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer (clinicaltrials.gov) - Jul 12, 2022
P2, N=124, Active, not recruiting, Sponsor: Pfizer
Trial completion date: Apr 2023 --> Aug 2023 | Trial primary completion date: Apr 2023 --> Aug 2023 Unknown status --> Active, not recruiting | Trial completion date: Dec 2019 --> Sep 2022
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: A Commentary on the "Duration of Oral Antibiotics Administration for Cetuximab-Induced Acneiform Eruption". (Pubmed Central) - Jul 10, 2022
[Dermatology. 2021;237(3):457-63], further elaborate on prevention and treatment measures of CIAE, and highlight the implications of CIAE on a patient's QoL.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. (Pubmed Central) - Jul 9, 2022
2021;237(3):457-63], further elaborate on prevention and treatment measures of CIAE, and highlight the implications of CIAE on a patient's QoL. PCC is well-tolerated with good induction success rate and reasonable PFS/OS in metastatic/recurrent disease.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono, Visudyne (verteporfin) / Novartis
Journal: Photoimmunotherapy Retains Its Anti-Tumor Efficacy with Increasing Stromal Content in Heterotypic Pancreatic Cancer Spheroids. (Pubmed Central) - Jul 9, 2022
This marked difference in efficacy is attributed to the ability of PICs to penetrate and distribute homogeneously within spheroids with a higher stromal content and the mechanistically different modes of action of the two formulations. This study thus demonstrates how the stromal content in PDAC spheroids directly impacts their responsiveness to PDT and proposes PIT to be a highly suited treatment option for desmoplastic tumors with particularly high degrees of stromal content.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Preclinical, Journal: Safety and tolerability of intravitreal cetuximab in young and adult rabbits. (Pubmed Central) - Jul 9, 2022
Thickness of the outer nuclear layer, inner nuclear layer, combined outer and inner nuclear layer and outer plexiform layer, and total retina, measured at the posterior pole, posterior pole/equator midpoint, equator, and ora serrata region, did not vary significantly between study eyes and control eyes (all P > 0.05, Bonferroni corrected). The results suggest that repeated intravitreal application of cetuximab did not result in any detected intraocular toxic or destructive effect in young and adult rabbits, concurring with the notion of an intraocular tolerability of cetuximab.
- | Journal: The close interaction between hypoxia-related proteins and metastasis in pancarcinomas. (Pubmed Central) - Jul 9, 2022
Lastly, we identified 23 drugs enrolled in clinical trials focused on metastatic disease treatment. Six of them were involved in advanced-stage clinical trials: aflibercept, bevacizumab, cetuximab, erlotinib, ipatasertib, and panitumumab.
- ||| Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Enrollment open, Metastases: SEAMARK: A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer (clinicaltrials.gov) - Jul 8, 2022
P2, N=104, Recruiting, Sponsor: Pfizer
Six of them were involved in advanced-stage clinical trials: aflibercept, bevacizumab, cetuximab, erlotinib, ipatasertib, and panitumumab. Not yet recruiting --> Recruiting
- | cisplatin / Generic mfg.
Journal: Treatment outcomes of standard (high dose) cisplatin and non-standard chemotherapy for locally advanced head and neck cancer. (Pubmed Central) - Jul 7, 2022
We demonstrated similar efficacy of lower dose weekly cisplatin and carboplatin/paclitaxel regimens and better safety profile of weekly cisplatin compared to standard HD cisplatin regimens for LA-HNSCC. Multicenter randomised control trials are required in HD cisplatin-ineligible patients.
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Stivarga (regorafenib) / Bayer, irinotecan / Generic mfg.
Change oncologist and start again with cetuximab immunotherapy and irinotecan. The disease is controlled by therapy from July 2020 until October 2021. Then the disease starts to grow again, so oral therapy with regorafenib is opted for from December 2021 to today. (Twitter) - Jul 7, 2022
- || Erbitux (cetuximab) / Eli Lilly, EMD Serono, irinotecan / Generic mfg.
Dear Prof. Andrea Cercek may I ask your help. My best friend 59 years old was diagnosed with posterior pelvic evisceration, october 2019 recurrence on vaginal and rectal stump, start of therapy with cetuximab and folfiri. (Twitter) - Jul 7, 2022
- || Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly, EMD Serono
Biomarker, Clinical, Journal: Plasma protein markers in advanced or metastatic colorectal cancer patients receiving chemotherapy with bevacizumab or cetuximab: Results from CALGB 80405 (Alliance). (Pubmed Central) - Jul 6, 2022
In this exploratory, hypothesis-generating analysis, the Angiome identified multiple prognostic biomarkers and two potential predictive biomarkers for mCRC patients enrolled in CALGB80405. PlGF and VEGF-D predicted lack of benefit from bevacizumab in a chemo-dependent manner.
- | Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: A Comprehensive Prognostic Model for Colorectal Cancer Liver Metastasis Recurrence After Neoadjuvant Chemotherapy. (Pubmed Central) - Jul 6, 2022
Our model is concise, comprehensive, and high efficient, which may contribute to better predicting the prognosis of patients with CRLMs with NACT before the liver resection. In addition, we observed an unbalanced distribution of HGPs as well.
- | Stivarga (regorafenib) / Bayer
Retrospective data, Journal, Real-world evidence: Hepatic arterial infusion chemotherapy plus regorafenib in advanced colorectal cancer: a real-world retrospective study. (Pubmed Central) - Jul 5, 2022
Regorafenib combined with Hepatic arterial infusion was effective and tolerable in patients with liver predominant metastasis of colorectal cancer. Hence, this therapy can be considered as an alternative for second- or subsequent lines of therapy in patients refractory to standard systemic chemotherapy.
- ||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: As part of the phase 3 BREAKWATER trial, the efficacy of encorafenib + cetuximab w/ or w/o SOC chemotherapy will be compared w/ that of chemotherapy alone in pts w/ BRAF V600E–mutated metastatic colorectal cancer. @skopetz @MDAndersonNews #crcsm #Oncology https://t.co/rS46GmBK7M (Twitter) - Jul 4, 2022
- ||| Oxaliplatin and Irinotecan were turn of the Century not 60s Cetuximab - late 2000's All three are predominantly used in GI cancers more than anything else. Lonsurf later still although not a major breakthrough. (Twitter) - Jul 3, 2022
- |||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Braftovi (encorafenib) / Ono Pharma, Pierre Fabre, Pfizer
Clinical: The efficacy of encorafenib + cetuximab w/ or w/o SOC chemotherapy will be compared w/ that of chemotherapy alone in pts w/ BRAF V600E–mutated metastatic colorectal cancer as part of the phase 3 BREAKWATER trial. @skopetz @MDAndersonNews #crcsm #Oncology https://t.co/n2NME09cg2 (Twitter) - Jul 3, 2022